Guardant Health is changing how cancer gets detected and monitored. Instead of requiring invasive tissue biopsies, the company’s liquid biopsy tests analyze fragments of tumor DNA circulating in the bloodstream. A simple blood draw can reveal which genetic mutations are driving a patient’s cancer, helping oncologists choose targeted therapies.
Founded in 2012, Guardant’s flagship product, Guardant360, was the first liquid biopsy approved by the FDA for comprehensive tumor profiling in advanced solid cancers. The test identifies mutations across dozens of genes and returns results in about a week. It’s now used by thousands of oncologists and has been ordered for hundreds of thousands of patients.
Guardant has also moved into early cancer detection with its Shield test, which screens for colorectal cancer from a blood sample. The FDA approved Shield in 2024, and the company is working on multi-cancer early detection tests that could eventually screen for multiple cancer types at once. Guardant trades on Nasdaq and generates over $600 million in annual revenue. The company’s vision is a world where cancer can be caught and monitored through routine blood work.
